Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 13, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The primary material change reported is a movement in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on March 9, 2007. The number of Ordinary Share ADRs held by the fund increased from 16,204,663 to 16,408,516. This transaction occurred at an average price of $55.63 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The Plan is a discretionary fund where all employees or former employees are potential beneficiaries. Two directors, Dr. J P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Investor Verification Points
- Verify the exact date of the fund movement (March 9, 2007) versus the notification date (March 13, 2007).
- Confirm the average transaction price of $55.63 against market data for that period.
- Review the total increase in ADR holdings (203,853 shares) to understand the scale of the fund's activity.
- Note that the directors' interest is indirect through the discretionary employee fund, not a direct personal transaction.